{"id":745193,"date":"2015-05-28T07:30:00","date_gmt":"2015-05-28T07:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-nanostring-announce-clinical-research-collaboration-to-develop-an-immune-related-gene-expression-assay-for-use-in-the-development-program-for-keytruda-pembrolizumab\/"},"modified":"2025-11-07T01:25:11","modified_gmt":"2025-11-07T06:25:11","slug":"merck-and-nanostring-announce-clinical-research-collaboration-to-develop-an-immune-related-gene-expression-assay-for-use-in-the-development-program-for-keytruda-pembrolizumab","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-nanostring-announce-clinical-research-collaboration-to-develop-an-immune-related-gene-expression-assay-for-use-in-the-development-program-for-keytruda-pembrolizumab\/","title":{"rendered":"Merck and NanoString Announce Clinical Research Collaboration to Develop an Immune-Related Gene Expression Assay for Use in the Development Program for KEYTRUDA\u00ae (pembrolizumab)"},"content":{"rendered":"<p class=\"bwalignc\">       Collaboration Builds on Merck\u2019s R&amp;D and NanoString\u2019s Biomarker        Development Leadership Positions in Immuno-Oncology     <\/p>\n<p class=\"bwalignc\">       Early Data Evaluating Immune-Related Signatures with KEYTRUDA in        Multiple Cancers to be Presented for the First Time at 2015 ASCO Annual        Meeting     <\/p>\n<p>KENILWORTH, N.J. &amp; SEATTLE&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE:MRK), known as MSD outside the United States and Canada, and<br \/>\n      NanoString Technologies, Inc. (NASDAQ:NSTG) today announced a clinical<br \/>\n      research collaboration to develop an assay that will optimize<br \/>\n      immune-related gene expression signatures and evaluate the potential to<br \/>\n      predict benefit from Merck\u2019s anti-PD-1 therapy, KEYTRUDA<sup>\u00ae<\/sup><br \/>\n      (pembrolizumab), in multiple tumor types. The collaboration between<br \/>\n      NanoString Technologies, Inc., a provider of life science tools for<br \/>\n      translational research and molecular diagnostic products, and Merck,<br \/>\n      through a subsidiary, will utilize NanoString\u2019s nCounter<sup>\u00ae<\/sup><br \/>\n      Analysis System to optimize gene expression signatures as part of the<br \/>\n      clinical development program for KEYTRUDA.\n    <\/p>\n<p>\n      \u201cOur commitment to advancing the science of immuno-oncology includes<br \/>\n      pursuing cutting-edge RNA and DNA approaches to identify a range of<br \/>\n      biomarkers, such as immune-related gene expression signatures, that in<br \/>\n      addition to PD-L1 expression, may help to identify patients who may be<br \/>\n      more likely to experience improved benefit with KEYTRUDA,\u201d said Dr. Eric<br \/>\n      Rubin, vice president and therapeutic area head, oncology early-stage<br \/>\n      development, Merck Research Laboratories. \u201cOur collaboration with<br \/>\n      NanoString Technologies is an important advancement for our early-stage,<br \/>\n      immuno-oncology development program. Early data exploring the predictive<br \/>\n      value of the NanoString-derived gene expression signatures with KEYTRUDA<br \/>\n      will be presented at ASCO 2015.\u201d\n    <\/p>\n<p>\n      \u201cWe are excited to work with Merck to help direct treatment with<br \/>\n      KEYTRUDA,\u201d said Brad Gray, president and chief executive officer of<br \/>\n      NanoString Technologies. \u201cNew approaches in immuno-oncology, like<br \/>\n      KEYTRUDA, have the potential to transform cancer care across many<br \/>\n      different tumor types. With our nCounter technology and <i>in vitro <\/i>diagnostic<br \/>\n      capability, NanoString is ideally positioned to address the critical<br \/>\n      challenge of matching patients to powerful new therapies. This<br \/>\n      collaboration with Merck complements our existing relationships with MD<br \/>\n      Anderson and the Cancer Immunotherapy Trials Network, and builds on our<br \/>\n      leadership position in immuno-oncology biomarker development.\u201d\n    <\/p>\n<p>\n      <b>Early Data on Immune-based Gene Expression Signatures at 2015 ASCO<br \/>\n      Annual Meeting<\/b>\n    <\/p>\n<p>\n      First-time presentations of data evaluating immune-based gene expression<br \/>\n      signatures developed using NanoString\u2019s nCounter<sup>\u00ae<\/sup> Analysis<br \/>\n      System, and their correlation to patient benefit with KEYTRUDA will be<br \/>\n      presented at this year\u2019s 51<sup>st<\/sup> Annual Meeting of the American<br \/>\n      Society of Clinical Oncology (May 29-June 2, 2015 in Chicago). The early<br \/>\n      data to be presented include findings in bladder cancer (Abstract<br \/>\n      #4502), advanced melanoma (Abstract #3001), gastric cancer (Abstract<br \/>\n      #3026), and head and neck cancer (Abstract #6017). These early data are<br \/>\n      based on an initial signature, the interferon-gamma response gene, which<br \/>\n      was derived from initial findings that expression of this immune<br \/>\n      response gene predicted response to KEYTRUDA in advanced melanoma<br \/>\n      patients. Additional signatures are in development based on extension of<br \/>\n      these initial findings.\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><sup><b>\u00ae<\/b><\/sup><b> (pembrolizumab)<\/b>\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab) is a humanized monoclonal antibody that blocks<br \/>\n      the interaction between PD-1 and its ligands, PD-L1 and PD-L2. By<br \/>\n      binding to the PD-1 receptor and blocking the interaction with the<br \/>\n      receptor ligands, KEYTRUDA releases the PD-1 pathway-mediated inhibition<br \/>\n      of the immune response, including the anti-tumor immune response.\n    <\/p>\n<p>\n      KEYTRUDA is indicated in the United States at a dose of 2 mg\/kg<br \/>\n      administered as an intravenous infusion over 30 minutes every three<br \/>\n      weeks for the treatment of patients with unresectable or metastatic<br \/>\n      melanoma and disease progression following ipilimumab and, if BRAF V600<br \/>\n      mutation positive, a BRAF inhibitor. This indication is approved under<br \/>\n      accelerated approval based on tumor response rate and durability of<br \/>\n      response. An improvement in survival or disease-related symptoms has not<br \/>\n      yet been established. Continued approval for this indication may be<br \/>\n      contingent upon verification and description of clinical benefit in the<br \/>\n      confirmatory trials.\n    <\/p>\n<p>\n      Merck is advancing a broad and fast-growing clinical development program<br \/>\n      for KEYTRUDA with more than 100 clinical trials \u2013 across more than 30<br \/>\n      tumor types and enrolling more than 16,000 patients \u2013 both as a<br \/>\n      monotherapy and in combination with other therapies.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b>\n    <\/p>\n<p>\n      Pneumonitis occurred in 12 (2.9%) of 411 patients with advanced melanoma<br \/>\n      receiving KEYTRUDA (the approved indication in the United States),<br \/>\n      including Grade 2 or 3 cases in 8 (1.9%) and 1 (0.2%) patients,<br \/>\n      respectively. Monitor patients for signs and symptoms of pneumonitis.<br \/>\n      Evaluate suspected pneumonitis with radiographic imaging. Administer<br \/>\n      corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA<br \/>\n      for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4<br \/>\n      pneumonitis.\n    <\/p>\n<p>\n      Colitis (including microscopic colitis) occurred in 4 (1%) of 411<br \/>\n      patients, including Grade 2 or 3 cases in 1 (0.2%) and 2 (0.5%) patients<br \/>\n      respectively, receiving KEYTRUDA. Monitor patients for signs and<br \/>\n      symptoms of colitis. Administer corticosteroids for Grade 2 or greater<br \/>\n      colitis. Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue<br \/>\n      KEYTRUDA for Grade 4 colitis.\n    <\/p>\n<p>\n      Hepatitis (including autoimmune hepatitis) occurred in 2 (0.5%) of 411<br \/>\n      patients, including a Grade 4 case in 1 (0.2%) patient, receiving<br \/>\n      KEYTRUDA. Monitor patients for changes in liver function. Administer<br \/>\n      corticosteroids for Grade 2 or greater hepatitis and, based on severity<br \/>\n      of liver enzyme elevations, withhold or discontinue KEYTRUDA.\n    <\/p>\n<p>\n      Hypophysitis occurred in 2 (0.5%) of 411 patients, including a Grade 2<br \/>\n      case in 1 and a Grade 4 case in 1 (0.2% each) patient, receiving<br \/>\n      KEYTRUDA. Monitor for signs and symptoms of hypophysitis. Administer<br \/>\n      corticosteroids for Grade 2 or greater hypophysitis. Withhold KEYTRUDA<br \/>\n      for Grade 2; withhold or discontinue for Grade 3; and permanently<br \/>\n      discontinue KEYTRUDA for Grade 4 hypophysitis.\n    <\/p>\n<p>\n      Nephritis occurred in 3 (0.7%) patients receiving KEYTRUDA, consisting<br \/>\n      of one case of Grade 2 autoimmune nephritis (0.2%) and two cases of<br \/>\n      interstitial nephritis with renal failure (0.5%), one Grade 3 and one<br \/>\n      Grade 4. Monitor patients for changes in renal function. Administer<br \/>\n      corticosteroids for Grade 2 or greater nephritis. Withhold KEYTRUDA for<br \/>\n      Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      Hyperthyroidism occurred in 5 (1.2%) of 411 patients, including Grade 2<br \/>\n      or 3 cases in 2 (0.5%) and 1 (0.2%) patients respectively, receiving<br \/>\n      KEYTRUDA. Hypothyroidism occurred in 34 (8.3%) of 411 patients,<br \/>\n      including a Grade 3 case in 1 (0.2%) patient, receiving KEYTRUDA.<br \/>\n      Thyroid disorders can occur at any time during treatment. Monitor<br \/>\n      patients for changes in thyroid function (at the start of treatment,<br \/>\n      periodically during treatment, and as indicated based on clinical<br \/>\n      evaluation) and for clinical signs and symptoms of thyroid disorders.<br \/>\n      Administer corticosteroids for Grade 3 or greater hyperthyroidism.<br \/>\n      Withhold KEYTRUDA for Grade 3; permanently discontinue KEYTRUDA for<br \/>\n      Grade 4 hyperthyroidism. Isolated hypothyroidism may be managed with<br \/>\n      replacement therapy without treatment interruption and without<br \/>\n      corticosteroids.\n    <\/p>\n<p>\n      Other clinically important immune-mediated adverse reactions can occur.<br \/>\n      The following clinically significant, immune-mediated adverse reactions<br \/>\n      occurred in less than 1% of patients treated with KEYTRUDA: exfoliative<br \/>\n      dermatitis, uveitis, arthritis, myositis, pancreatitis, hemolytic<br \/>\n      anemia, partial seizures arising in a patient with inflammatory foci in<br \/>\n      brain parenchyma, adrenal insufficiency, myasthenic syndrome, optic<br \/>\n      neuritis, and rhabdomyolysis.\n    <\/p>\n<p>\n      For suspected immune-mediated adverse reactions, ensure adequate<br \/>\n      evaluation to confirm etiology or exclude other causes. Based on the<br \/>\n      severity of the adverse reaction, withhold KEYTRUDA and administer<br \/>\n      corticosteroids. Upon improvement of the adverse reaction to Grade 1 or<br \/>\n      less, initiate corticosteroid taper and continue to taper over at least<br \/>\n      1 month. Restart KEYTRUDA if the adverse reaction remains at Grade 1 or<br \/>\n      less. Permanently discontinue KEYTRUDA for any severe or Grade 3<br \/>\n      immune-mediated adverse reaction that recurs and for any<br \/>\n      life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA may cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      For the treatment of advanced melanoma, KEYTRUDA was discontinued for<br \/>\n      adverse reactions in 6% of 89 patients who received the recommended dose<br \/>\n      of 2 mg\/kg and 9% of 411 patients across all doses studied. Serious<br \/>\n      adverse reactions occurred in 36% of patients receiving KEYTRUDA. The<br \/>\n      most frequent serious adverse drug reactions reported in 2% or more of<br \/>\n      patients were renal failure, dyspnea, pneumonia, and cellulitis.\n    <\/p>\n<p>\n      The most common adverse reactions (reported in \u226520% of patients) were<br \/>\n      fatigue (47%), cough (30%), nausea (30%), pruritus (30%), rash (29%),<br \/>\n      decreased appetite (26%), constipation (21%), arthralgia (20%), and<br \/>\n      diarrhea (20%).\n    <\/p>\n<p>\n      The recommended dose of KEYTRUDA is 2 mg\/kg administered as an<br \/>\n      intravenous infusion over 30 minutes every three weeks until disease<br \/>\n      progression or unacceptable toxicity. No formal pharmacokinetic drug<br \/>\n      interaction studies have been conducted with KEYTRUDA. It is not known<br \/>\n      whether KEYTRUDA is excreted in human milk. Because many drugs are<br \/>\n      excreted in human milk, instruct women to discontinue nursing during<br \/>\n      treatment with KEYTRUDA. Safety and effectiveness of KEYTRUDA have not<br \/>\n      been established in pediatric patients.\n    <\/p>\n<p>\n      <b>About&nbsp;NanoString Technologies, Inc.<\/b>\n    <\/p>\n<p>\n      NanoString Technologies provides life science tools for translational<br \/>\n      research and molecular diagnostic products. The company&#8217;s nCounter<br \/>\n      Analysis System has been employed in life sciences research since it was<br \/>\n      first introduced in 2008 and has been cited in over 700 peer-reviewed<br \/>\n      publications. The nCounter Analysis System offers a cost-effective way<br \/>\n      to easily profile the expression of hundreds of genes, proteins, miRNAs,<br \/>\n      or copy number variations, simultaneously with high sensitivity and<br \/>\n      precision, facilitating a wide variety of basic research and<br \/>\n      translational medicine applications, including biomarker discovery and<br \/>\n      validation. The company&#8217;s technology has also been applied to diagnostic<br \/>\n      use. The Prosigna Breast Cancer Prognostic Gene Signature Assay together<br \/>\n      with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a<br \/>\n      prognostic indicator for distant recurrence of breast cancer. For more<br \/>\n      information, please visit&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.nanostring.com&amp;esheet=51111997&amp;newsitemid=20150528005740&amp;lan=en-US&amp;anchor=www.nanostring.com&amp;index=1&amp;md5=7a53b826d6733196e00242d041c3da18\" rel=\"nofollow\">www.nanostring.com<\/a>.\n    <\/p>\n<p>\n      <b>NanoString Technologies, Inc. Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This press release contains forward-looking statements within the<br \/>\n      meaning of the Private Securities Litigation Reform Act of 1995,<br \/>\n      including statements regarding the likelihood of this collaboration to<br \/>\n      translate genomic discoveries to diagnostic assays,&nbsp;and the potential to<br \/>\n      develop diagnostic assays on the nCounter platform that will predict<br \/>\n      response to KEYTRUDA and other anti-PD-1 therapies. Forward-looking<br \/>\n      statements are subject to risks and uncertainties that could cause<br \/>\n      actual results to differ materially and reported results should not be<br \/>\n      considered as an indication of future performance. These risks and<br \/>\n      uncertainties include, but are not limited to: risks associated with<br \/>\n      keeping pace with rapidly changing technology and customer requirements;<br \/>\n      risks regarding the company&#8217;s ability to successfully introduce new<br \/>\n      products; risks that new market opportunities may not develop as quickly<br \/>\n      as expected; risks associated with competition in marketing and selling<br \/>\n      products; risks of increased regulatory requirements; as well as the<br \/>\n      other risks set forth in the company&#8217;s filings with the&nbsp;Securities and<br \/>\n      Exchange Commission. These forward-looking statements speak only as of<br \/>\n      the date hereof.&nbsp;NanoString Technologies&nbsp;disclaims any obligation to<br \/>\n      update these forward-looking statements.\n    <\/p>\n<p>\n      The&nbsp;NanoString Technologies&nbsp;logo,&nbsp;NanoString,&nbsp;NanoString Technologies,<br \/>\n      nCounter and Prosigna are either registered trademarks or trademarks<br \/>\n      of&nbsp;NanoString Technologies, Inc.\n    <\/p>\n<p>\n      <b>Merck\u2019s Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck Oncology,<br \/>\n      helping people fight cancer is our passion and supporting accessibility<br \/>\n      to our cancer medicines is our commitment.&nbsp;Our focus is on pursuing<br \/>\n      research in immuno-oncology and we are accelerating every step in the<br \/>\n      journey \u2013 from lab to clinic \u2013 to potentially bring new hope to people<br \/>\n      with cancer. For more information about our oncology clinical trials,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51111997&amp;newsitemid=20150528005740&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=2&amp;md5=6b58cc0c33a610bf92ff4244b45097b2\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside of the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to healthcare through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2F&amp;esheet=51111997&amp;newsitemid=20150528005740&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=3&amp;md5=8e1f4d48f1953187b8496716f8119f09\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Fmerck&amp;esheet=51111997&amp;newsitemid=20150528005740&amp;lan=en-US&amp;anchor=Twitter&amp;index=4&amp;md5=8a366bdcb6c651119b1162ecc41975c2\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2Fmerckbewell&amp;esheet=51111997&amp;newsitemid=20150528005740&amp;lan=en-US&amp;anchor=Facebook&amp;index=5&amp;md5=94e8dbb3c3d4e22a2e5f2c8f7d8a6157\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2Fmerck&amp;esheet=51111997&amp;newsitemid=20150528005740&amp;lan=en-US&amp;anchor=YouTube&amp;index=6&amp;md5=aa664949f4482b03e5cc21cdb858f052\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Merck Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include, but are not limited to, general<br \/>\n      industry conditions and competition; general economic factors, including<br \/>\n      interest rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and healthcare legislation in the<br \/>\n      United States and internationally; global trends toward healthcare cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2014 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51111997&amp;newsitemid=20150528005740&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=7&amp;md5=228d22c311870f5e23d741d92edfe38a\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=51111997&amp;newsitemid=20150528005740&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=8&amp;md5=08f96b61aab73f5e74132e6d226a7229\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><\/a><b><br \/>\n      and the Medication Guide for KEYTRUDA at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=51111997&amp;newsitemid=20150528005740&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=9&amp;md5=428abc91cbb39b4befbf12204d946d84\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><\/a>\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150528005740r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck Media Relations:<br \/>Pamela Eisele, 267-305-3558<br \/>Claire        Mulhearn, 908-236-1118<br \/>or<br \/>Merck Investor Relations:<br \/>Justin        Holko, 908-740-1879<br \/>or<br \/>NanoString Investor\/Media Relations:<br \/>Leigh        Salvo, 415-513-1281     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, and NanoString Technologies, Inc. (NASDAQ:NSTG) today announced a clinical research collaboration to develop an assay that will optimize immune-related gene expression signatures and evaluate the potential to predict benefit from Merck\u2019s anti-PD-1 therapy, KEYTRUDA \u00ae (pembrolizumab), in multiple tumor types. The collaboration between NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, and Merck, through a subsidiary, will utilize NanoString\u2019s nCounter \u00ae Analysis System to optimize gene expression signatures as part of the clinical development program for KEYTRUDA. \u201cOur commitment to advancing the science of immuno-oncology includes pursuing cutting-edge RNA and DNA approaches to identify a range of biomarkers, such as immune-related gene expression signatures, that in addition to PD-L1 expression, may help to identify patients who may be more<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,138,55,289],"class_list":["post-745193","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-oncology-newsroom","tag-prescription-medicine-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck and NanoString Announce Clinical Research Collaboration to Develop an Immune-Related Gene Expression Assay for Use in the Development Program for KEYTRUDA\u00ae (pembrolizumab) - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-nanostring-announce-clinical-research-collaboration-to-develop-an-immune-related-gene-expression-assay-for-use-in-the-development-program-for-keytruda-pembrolizumab\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck and NanoString Announce Clinical Research Collaboration to Develop an Immune-Related Gene Expression Assay for Use in the Development Program for KEYTRUDA\u00ae (pembrolizumab) - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, and NanoString Technologies, Inc. (NASDAQ:NSTG) today announced a clinical research collaboration to develop an assay that will optimize immune-related gene expression signatures and evaluate the potential to predict benefit from Merck\u2019s anti-PD-1 therapy, KEYTRUDA \u00ae (pembrolizumab), in multiple tumor types. The collaboration between NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, and Merck, through a subsidiary, will utilize NanoString\u2019s nCounter \u00ae Analysis System to optimize gene expression signatures as part of the clinical development program for KEYTRUDA. \u201cOur commitment to advancing the science of immuno-oncology includes pursuing cutting-edge RNA and DNA approaches to identify a range of biomarkers, such as immune-related gene expression signatures, that in addition to PD-L1 expression, may help to identify patients who may be more\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-nanostring-announce-clinical-research-collaboration-to-develop-an-immune-related-gene-expression-assay-for-use-in-the-development-program-for-keytruda-pembrolizumab\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"11 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-nanostring-announce-clinical-research-collaboration-to-develop-an-immune-related-gene-expression-assay-for-use-in-the-development-program-for-keytruda-pembrolizumab\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-nanostring-announce-clinical-research-collaboration-to-develop-an-immune-related-gene-expression-assay-for-use-in-the-development-program-for-keytruda-pembrolizumab\\\/\",\"name\":\"Merck and NanoString Announce Clinical Research Collaboration to Develop an Immune-Related Gene Expression Assay for Use in the Development Program for KEYTRUDA\u00ae (pembrolizumab) - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2015-05-28T07:30:00+00:00\",\"dateModified\":\"2025-11-07T06:25:11+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-nanostring-announce-clinical-research-collaboration-to-develop-an-immune-related-gene-expression-assay-for-use-in-the-development-program-for-keytruda-pembrolizumab\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-nanostring-announce-clinical-research-collaboration-to-develop-an-immune-related-gene-expression-assay-for-use-in-the-development-program-for-keytruda-pembrolizumab\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-nanostring-announce-clinical-research-collaboration-to-develop-an-immune-related-gene-expression-assay-for-use-in-the-development-program-for-keytruda-pembrolizumab\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck and NanoString Announce Clinical Research Collaboration to Develop an Immune-Related Gene Expression Assay for Use in the Development Program for KEYTRUDA\u00ae (pembrolizumab)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck and NanoString Announce Clinical Research Collaboration to Develop an Immune-Related Gene Expression Assay for Use in the Development Program for KEYTRUDA\u00ae (pembrolizumab) - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-nanostring-announce-clinical-research-collaboration-to-develop-an-immune-related-gene-expression-assay-for-use-in-the-development-program-for-keytruda-pembrolizumab\/","og_locale":"en_US","og_type":"article","og_title":"Merck and NanoString Announce Clinical Research Collaboration to Develop an Immune-Related Gene Expression Assay for Use in the Development Program for KEYTRUDA\u00ae (pembrolizumab) - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, and NanoString Technologies, Inc. (NASDAQ:NSTG) today announced a clinical research collaboration to develop an assay that will optimize immune-related gene expression signatures and evaluate the potential to predict benefit from Merck\u2019s anti-PD-1 therapy, KEYTRUDA \u00ae (pembrolizumab), in multiple tumor types. The collaboration between NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, and Merck, through a subsidiary, will utilize NanoString\u2019s nCounter \u00ae Analysis System to optimize gene expression signatures as part of the clinical development program for KEYTRUDA. \u201cOur commitment to advancing the science of immuno-oncology includes pursuing cutting-edge RNA and DNA approaches to identify a range of biomarkers, such as immune-related gene expression signatures, that in addition to PD-L1 expression, may help to identify patients who may be more","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-nanostring-announce-clinical-research-collaboration-to-develop-an-immune-related-gene-expression-assay-for-use-in-the-development-program-for-keytruda-pembrolizumab\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:11+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-nanostring-announce-clinical-research-collaboration-to-develop-an-immune-related-gene-expression-assay-for-use-in-the-development-program-for-keytruda-pembrolizumab\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-nanostring-announce-clinical-research-collaboration-to-develop-an-immune-related-gene-expression-assay-for-use-in-the-development-program-for-keytruda-pembrolizumab\/","name":"Merck and NanoString Announce Clinical Research Collaboration to Develop an Immune-Related Gene Expression Assay for Use in the Development Program for KEYTRUDA\u00ae (pembrolizumab) - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2015-05-28T07:30:00+00:00","dateModified":"2025-11-07T06:25:11+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-nanostring-announce-clinical-research-collaboration-to-develop-an-immune-related-gene-expression-assay-for-use-in-the-development-program-for-keytruda-pembrolizumab\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-nanostring-announce-clinical-research-collaboration-to-develop-an-immune-related-gene-expression-assay-for-use-in-the-development-program-for-keytruda-pembrolizumab\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-nanostring-announce-clinical-research-collaboration-to-develop-an-immune-related-gene-expression-assay-for-use-in-the-development-program-for-keytruda-pembrolizumab\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck and NanoString Announce Clinical Research Collaboration to Develop an Immune-Related Gene Expression Assay for Use in the Development Program for KEYTRUDA\u00ae (pembrolizumab)"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"8cf56de9-ea71-4f8a-abc2-b2373b756b21","news_item_aria_label":"","media_files":[{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_events\/2015\/05\/1\/merck_logo.jpg","size":"21167","File Upload":""},{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_events\/2015\/05\/1\/NanoString_Logo.jpg","size":"20732","File Upload":""}],"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-and-NanoString-Announce-Clinical-Research-Collaboration-to-Develop-an-Immune-Related-Gene-Expression-Assay-for-Use-in-the-Devel-48F81.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745193","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745193\/revisions"}],"predecessor-version":[{"id":3674640,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745193\/revisions\/3674640"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745193"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745193"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}